Drugs / WX390
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03730142 | Oct 2018 → Jul 2020 | — | Shanghai Jiatan Pharmatech Co., Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06117566 | Nov 2022 → Nov 2025 overdue | neoplasm | Shanghai Jiatan Pharmatech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06132932 | Jun 2021 → Jan 2023 | — | Shanghai Jiatan Pharmatech Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06124963 | Aug 2023 → Dec 2025 overdue | gastric adenocarcinoma | Shanghai Jiatan Pharmatech Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06117540 | May 2021 → Jun 2025 overdue | cancer | Shanghai Jiatan Pharmatech Co., Ltd | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07392060 | Feb 2026 → Sep 2029 expected | cervical cancer | Shanghai Jiatan Pharmatech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WX390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06124963 ↗ |
| Known as | WXFL10030390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03730142 ↗ |
| Action | Inhibit | “inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR)” NCT03730142 ↗ |
| Modality | Small molecule | “novel oral small molecular” NCT03730142 ↗ |
| Route | Oral | “WXFL10030390 continuous oral dosing” NCT03730142 ↗ |